IAV-IN-5
IAV-IN-5 is an orally active inhibitor of influenza A virus (IAV). IAV-IN-5 inhibits viral replication, blocks virus-induced apoptosis, oxidative stress and cytokine storm, and regulates host immune signaling pathways. IAV-IN-5 reduces viral load and inflammatory cytokine levels in lung tissues of IAV-infected mouse models, alleviates body weight loss and pulmonary pathological damage. IAV-IN-5 can be used in studies related to influenza A virus infection.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 3038861-11-6
- Formule: C22H23NO3S
- Masse moléculaire:381.49
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
IC50 & Target
[1]|
NF-κB |
IL-4 |
IL-6 |
TLR3 |
iNOS |
In Vitro
IAV-IN-5 (compound 3h) (25-100 μM; 24 h post-infection) dose-dependently inhibits RIG-I protein expression and phosphorylated NF-κB levels in A/Weiss/43 (H1N1)-infected A549 cells, blocking activation of the NF-κB inflammatory signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 cells infected with A/Weiss/43 (H1N1)
-
Concentration:25, 50, 100 μM
-
Incubation Time:24 h post-infection
-
Result:Dose-dependently inhibited RIG-I protein expression compared to the virus control group.
Significantly reduced pNF-κB levels compared to the virus control group.
In Vivo
IAV-IN-5 (100 mg/kg/d; i.g.; daily; 6 days) shows excellent in vivo safety in healthy BALB/c mice, with no observable organ toxicity or changes in blood or serum biochemical parameters[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (female, 5 weeks old, 13-17 g, intranasal inoculation with A/Weiss/43 H1N1 virus)[1]
-
Dosage:25 mg/kg/d; 50 mg/kg/d; 100 mg/kg/d
-
Administration:i.g.; daily; 6 days
-
Result:Alleviated virus-induced weight loss and improved mouse survival.
Reduced hemorrhagic lesions and edema; 100 mg/kg/d caused only mild edema, similar to oseltamivir.
Inhibited lung index by 23.76% (25 mg/kg/d), 38.24% (50 mg/kg/d), and 50.26% (100 mg/kg/d); high-dose inhibition exceeded oseltamivir.
Mitigated alveolar wall thickening, interstitial edema, and inflammatory infiltration; 100 mg/kg/d maintained intact alveolar structure comparable to oseltamivir.
Decreased influenza virus NP protein staining in lung tissue dose-dependently, with the weakest signal at 100 mg/kg/d.
Reduced mRNA levels of viral NP and M2 genes in lung tissue on days 2, 4, and 6 post-infection at all doses.
Downregulated mRNA expression of inflammatory factors (RIG-I, TLR3, IRF3, ASC, iNOS, IL-4, IL-6, IFN-α) in lung tissue on day 6 post-infection at all doses.
Diminished apoptotic cells in lung tissue dose-dependently; 100 mg/kg/d was comparable to oseltamivir.
-
Animal Model:BALB/c (female, 5 weeks old, 13-17 g)[1]
-
Dosage:100 mg/kg/d
-
Administration:i.g.; daily; 6 days
-
Result:Showed no obvious pathological changes, tissue damage, cell degeneration/necrosis, or inflammatory cell infiltration.
Maintained routine blood parameters within normal physiological ranges.
Kept serum biochemical indices close to normal control levels.
Chemical Information
-
CAS No. 3038861-11-6
-
Masse moléculaire 381.49
-
Formule C22H23NO3S
-
SMILES
O=S(C1=CC=C(C)C=C1)(N(C2=C(C)[C@@]3([H])CCCC([C@@]23[H])=O)C4=CC=CC=C4)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)